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All the molecules have been designed on the basis of previously reported active pharmacophores via molecular 
hybridization. A convenient protocol for the preparation of N-((2-(piperazin-1-yl) quinolin-3-yl)methyl)aniline derivatives via 
mutli-step synthesis has been described. Spectral analysis using Mass, 1H and 13C NMR spectral techniques have been studied 
in order to confirm the structure of synthesized end molecules. All synthesized compounds have been screened for in vitro 
antimicrobial, antimalarial and antitubercular activities. Structural activity relationship study (SAR) have also been discussed. 
Interestingly, target molecules are found to show good to excellent antibacterial, antifungal and antimalarial potency. 
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Heterocycles comprising a nitrogen atom have 
interesting medicinal and pharmaceutical properties1,2. 
Among them, quinoline derivatives are exceptional 
nitrogen-containing heterocycles which concerned 
specific attention having superior place as building 
blocks of various pharmaceutical agents, natural 
products and biological active molecules3-5. 
Quinoline is a significant nucleus which has attracted 
the attention of medicinal chemists due to its variable 
pharmacological activities. Easy functionalization of 
various ring positions of quinoline makes it an attractive 
synthetic building block for design and synthesis of new 
drugs. Additionally, quinolines are considered as 
an interesting group of compounds, many of which 
have widespread pharmacological actions such as 
antitubercular6-9, anti-microbial10-13, antihypertensive14,15, 
anti-inflammatory16-19, anticancer20,21, anti-convulsant22-23, 
and antioxidant24-26 activities. Quinoline scaffolds get 
much attention due to their miscellaneous therapeutic 
and pharmacological properties such as antiatherosclerotic, 
vasodilator, geroprotective, bronchodilator and 
hepatoprotective activity27-29. Numerous strategies have 
been considered for the preparation of quinoline 
derivatives like Skraup, Meth-Cohn, Conrad-Limpach, 
Combes, Doebner-von Miller, and Pfitzinger syntheses. 
Out of them, Meth-Cohn protocol for the synthesis of 
substituted 2-chloro-3-formylquinolines get much 
attention in recent years30. 
In recent years, the expansion of antimicrobial  
agents becomes one of the leading areas of antibacterial 
research, because of their resistance to the existing 
antibacterial and antifungal drugs31-33. Thus the development 
of new and novel antimicrobial agents are highly 
essential to survive this situation. This is the area why it 
seems crucial in order to examine for novel 
antimicrobial molecules with new mechanisms of action, 
to overcome antimicrobial resistance34. 
Similarly, malaria is an infectious disease caused 
by a parasite (Plasmodium) that occurs in tropical and 
subtropical regions. The World Health Organization 
(WHO) estimates that half of the world population is 
at risk of malarial infection35. Since the discovery of 
the natural product quinine, many compounds with a 
quinoline scaffold have displayed good antimalarial 
activity, leading to the development of effective 
antimalarial agents, including chloroquine, amodiaquine, 
pamaquine and mefloquine (Figure 1)36-38. Nowadays, 
these drugs are falling to resistance in some parts of 
the world. The most potent Artemisinin and its 
derivatives, widely used in combination therapies 
for curing malaria worldwide are also now falling 
to resistance. 
Furthermore, Tuberculosis (TB) is one of the most 
deadly diseases that kills over one million people each 




year and infects one-third of the world’s population. 
Since the last 50 years, the same long-duration, 
multidrug treatment plan is being followed for the 
treatment of tuberculosis39. Recently, compounds 
such as ciprofloxacin, gemifloxacin, levofloxacin, 
moxifloxacin, norfloxacin and ofloxacin are used  
for treatment of M. TB (Figure 2)40. Nowadays the 
development of resistance to these antibiotics creates 
a need for new therapeutic strategies to combat  
M. tuberculosis. 
During the last decade, continues efforts in this 
field have led to various effective molecules 
succeeding to clinical trials. Due to such efforts, after 
40 years, a new drug, bedaquiline (I), from the 
diarylquinoline class, with a new and innovative 
mechanism of action, was approved by U.S. Food and 
Drug Administration (US-FDA) for treatment of 
MDR-TB41. Bedaquiline exhibits excellent anti-TB 
potency with a minimum inhibitory concentration 
(MIC) of 0.1 μM. It has dynamic activity against 
various strains which are resistant to several of the 
first-line drugs42. Because of this, many scientist have 
actively worked on modifications of the quinoline 
scaffold, toward the development of promising anti-
tuberculosis agents (Figure 3)43-46. In addition, newly 
approved anti-TB drug, bedaquiline (I) and and new 
bedaquiline analouge (II) suggest that 3-substituted 
quinolines tend to show promising anti-TB activity. 
Furthermore, a most potent heterocyclic secondary 
amine called piperazine gets much attention because of 
its wide range of biological activities like antianginal47,48, 
anticancer49, antihistamine50, antidepressant51-54, 
antipsychotic55, analgesic and anti-inflammatory56. 
Molecular hybridization is well known concept for 
the design and development of drug molecules which 
includes the combination of different pharmacophores 
of bioactive natural or synthetic substances into a 
single new hybrid compound with improved affinity 
and potency as compared to the parent drug molecules57. 
Additionally, this approach can result in compounds 
having different and/or dual modes of action, altered 
selectivity profile and decreased undesired side 
effects58 (Figure 4). 
Inspired by the above facts the present work 
proposed the design and synthesis of N-((2-(piperazin-1-
yl)quinolin-3-yl)methyl)aniline derivatives 6(A-L) 
 
 













Figure 4 — Design of target molecules via molecular hybridization 
 




achieved via reductive amination of tert-butyl 4-(3-
formylquinolin-2-yl)piperazine-1-carboxylate (3) with 
different amines 4(A-L) followed by de-protection of 






Materials and Methods 
All reagents were used as obtained from 
commercial suppliers without additional purification. 
Melting points (mp, °C) of all the synthesized 
compounds were determined on an electrothermal 
apparatus in open capillaries and are uncorrected. The 
purity of synthesized compounds was checked using 
precoated TLC plates (Merck Keiselgel F254) and 
visualization was attained via UV light. The FTIR 
spectra were recorded on IR affinity-1 FTIR 
(Shimadzu) spectrometer in KBr and wave numbers 
(ν max) are reported in cm-1 1H-NMR spectra were 
scanned on Bruker ADVANCE II NMR spectrometer 
operating at 400 MHz using DMSO-d6 as solvent  
and tetramethylsilane (TMS) as internal standard. 
Chemical shift (δ) values are expressed in parts per 
million (ppm) and coupling constants (J) are reported 
in Hertz (Hz). Mass spectra were recorded on 
WatersQuadrupole Detector (TDQ). 
 
Procedure of synthesis of 2-chloroquinoline-3-
carbaldehyde, 2 
In a 3 neck RBF, POCl3 (9.5eq) was added drop-
wise into DMF (10V) at 0 °C. The reaction mixture 
was stirred for 10 min and then acetanilide was added. 
Heat the reaction mixture at 80 °C for 6 h. The 
product formation was checked by TLC. After 
completion of the reaction, the reaction mixture was 
cooled to room temperature and quenched in crushed 
ice with stirring. A yellow solid was observed, which 
was filtered off and washed with water. The yellow 
solid was triturated with pentane to get pure product, 
which was directly used for next step without further 
purification. Yield 78%, Yellow Solid, m.p. 202 °C, 
1H-NMR (400 MHZ, CDCl3), 10.5 (s,1H), 8.79 
(s,1H), 8.09-8.11 (d, 1H, J = 8.4 Hz), 8.00-8.02  
(d, 1H, J = 8 Hz), 7.90-7.93 (t, 1H, J = 14.4 Hz), 7.66-
7.70 (t, 1H, J = 14.8 Hz). MS (ESI) m/z for (191.01): 
192.28 (M+H)+. 
 
Synthesis of tert-butyl 4-(3-formylquinolin-2-
yl)piperazine-1-carboxylate, 3 
To a stirred solution of 2-chloroquinoline-3-
carbaldehyde (2) (1eq) in DMF (10V), K2CO3 (2.5eq) 
was added and stirred the reaction mixture for 20 min 
at room temperature. After that, tert-butyl piperazine-
1-carboxylate (2eq) was added and heated the reaction 
mixture at 110 °C for 5 h. The product formation was 
checked by TLC. After completion of the reaction, the 
reaction mixture was cooled to room temperature  
and quenched in crushed ice and extracted with  
ethyl acetate. The solvent was dried over sodium 
sulphate and evaporated under dryness to get crude 
product. The crude product was purified by column 
chromatography. The product was eluted in 10% ethyl 
acetate in hexane. Yield 81%, Pale Yellow Solid, m.p. 
198 °C. 1H-NMR (400 MHZ, CDCl3) 10.21 (s,1H), 8.54 
(s,1H), 7.83-7.86 (t, 1H, J = 14.8 Hz), 7.72-7.76 (t, 1H,  
J = 15.6 Hz), 7.41-7.44 (t, 1H, J = 15 Hz), 3.67-3.69 
(t, 4H, J = 9.6 Hz), 3.46-3.49 (t, 4H, J = 9.6 Hz), 1.51 
(s, 9H). MS (ESI) m/z for (341.17): 342.69 (M+H)+. 
 
 
Scheme I — Synthesis of quinoline hybride derivatives 
 




Synthesis of tert-butyl 4-(3-((phenylamino)methyl) 
quinolin-2-yl)piperazine-1-carboxylate derivatives, 
5(A-L) 
To a stirred solution of Synthesis of tert-butyl 4-(3-
formylquinolin-2-yl)piperazine-1-carboxylate (3) (1eq) 
in methanol followed by addition of amines (1.2eq). 
After that catalytic amount of acetic acid was added 
and stirred the reaction mixture for 1 h at room 
temperature. The intermediate formation was checked 
by TLC. After that, reaction mixture was cooled at  
0 °C and stirred for 10 min and then NaCNBH3 (2eq) 
was added and stirred further at room temperature for 
1 h. After completion of the reaction, the reaction 
mixture was then quenched in crushed ice and 
extracted with ethyl acetate. The crude product was 
purified by column chromatography. 
 
Synthesis of N-((2-(piperazin-1-yl)quinolin-3-
yl)methyl)aniline derivatives, 6(A-L) 
To a stirred solution of tert-butyl 4-(3-
((phenylamino)methyl)quinolin-2-yl)piperazine-1-
carboxylate derivatives 5(A-L) in 1,4-dioxane (10V) 
at 0 °C, 4M HCl in 1,4-dioxane (10V) was added 
drop-wise and stirred the reaction mixture for 2 h at 
room temperature. The product formation was 
checked by TLC. After completion of the reaction, the 
reaction mixture was evaporated to dryness to get 
crude product and basify the reaction mixture with aq. 
sodium bicarbonate and extracted with DCM. 
Evaporate DCM layer under vacuum to get pure 
products 6(A-L) after trituration with n-pentane. 
4-Fluoro-3-methyl-N-((2-(piperazin-1-yl)quinolin- 
3-yl)methyl)aniline, 6A: Yellow solid, IR νmax (KBr) 
cm-1: 3371.68, 2947.33, 2754.44, 1643.41, 1504.53, 
1449.61, 1265.35, 1033.88, 941.29, 779.27. 1H-NMR 
(400MHz, DMSO-d6): δH (ppm) 9.34 (s, 1H), 8.34  
(s, 1H), 7.93-7.91 (d, 1H, J = 8 Hz), 7.86-7.84 (d, 1H, 
J = 8 Hz), 7.71-7.67 (t, 1H, J = 15.2 Hz), 7.49-7.45  
(t, 1H, J = 15.2 Hz), 7.28-7.26 (d, 1H, J = 8 Hz), 6.90-
6.85 (t, 1H, J = 18.4 Hz), 6.64 (s, 1H), 6.49 (s, 1H), 
4.38 (s, 1H), 3.32 (s, 4H), 2.12 (s, 4H), 1.60 (s, 3H). 
13C-NMR (100 MHz, DMSO): δC (ppm) 14.35, 42.44, 
47.20, 115.26, 116.13, 122.75, 124.81, 125.98, 
126.31, 127.58, 127.77, 129.68, 131.02, 141.32, 
157.76. MS (ESI) m/z for (350.19): 351.5 (M+H)+. 
Elemental Analysis: Calculated for C21H23FN4 
(350.19): C 71.98%, H 6.62%, N 15.99%; Found: C 
71.95%, H 6.61%, N 15.96%. 
3,4-Dimethoxy-N-((2-(piperazin-1-yl)quinolin-3-
yl)methyl)aniline, 6B: Dark brown solid, 
IR νmax (KBr) cm
-1: 3376.28, 2948.12, 2755.74, 
1647.49, 1544.13, 1449.61, 1268.24, 1039.81, 945.26, 
781.57. 1H-NMR (400MHz, DMSO-d6): δH (ppm) 
11.06 (s, 1H), 9.38 (s, 1H), 8.52 (s, 1H), 7.90-7.91  
(d, 1H, J = 8 Hz), 7.86-7.84 (d, 1H, J = 8 Hz), 7.71-
7.67 (t, 1H, J = 15.2 Hz), 7.49-7.85 (t, 2H, J = 19.6 
Hz), 7.74-7.70 (t, 1H, J = 14.8 Hz), 7.52-7.49 (t, 1H, J 
= 18.4 Hz), 6.86-6.76 (m, 3H), 6.64 (s, 1H), 4.54 (s, 
2H), 3.62 (s, 6H), 3.52 (s, 4H), 3.30 (s, 4H). 13C-NMR 
(100 MHz, DMSO): δC (ppm) 42.10, 45.28, 51.40, 
56.14, 97.61, 108.10, 112.82, 121.13, 122.76, 123.40, 
127.35, 127.57, 129.15, 135.90, 138.21, 140.92, 
148.40, 150.60, 156.62. MS (ESI) m/z for (378.21): 
379.4 (M+H)+. Elemental Analysis: Calculated for 
C22H26N4O2 (378.21): C 69.82%, H 6.92%, N 
14.80%; Found: C 69.81%, H 6.90%, N 14.78%. 
 
3,4-Difluoro-N-((2-(piperazin-1-yl)quinolin-3-
yl)methyl) aniline, 6C: Light brown solid, IR νmax 
(KBr) cm-1: 3340.82, 28.23.88, 2615.56, 1643.41, 
1550.82, 1435.09, 1265.35, 1033.88, 941.29, 771.55. 
1H-NMR (400MHz,MeOD): δH (ppm) 8.79  
(s, 1H), 8.23-8.21 (d, 1H, J = 8.8 Hz), 8.05-8.03  
(d, 1H, J = 8 Hz), 7.99-7.95 (t, 1H, J = 15.6 Hz), 7.74-
7.70 (t, 1H, J = 15.2 Hz), 7.09-7.02 (m, 1H), 6.67-
6.62 (m, 1H), 6.50-6.48 (d, 1H, J = 9.2 Hz), 4.51  
(s, 2H), 4.15-4.12 (t, 4H, J = 9.6 Hz), 3.62-3.59  
(t, 4H, J = 9.6 Hz). 13C-NMR (100 MHz, DMSO): δC 
(ppm) 42.10, 45.48, 51.20, 103.62, 114.15, 115.46, 
121.35, 122.64, 123.14, 127.35, 127.72, 129.51, 
135.90, 137.19, 144.82, 147.18, 148.45, 155.45. MS 
(ESI) m/z for (354.17): 355.2 (M+H)+ Elemental 
Analysis: Calculated for C20H20N4F2 (354.17): C 
67.78%, H 5.69%, N 15.81%; Found: C 67.75%, H 
5.67%, N 15.80%. 
3-Chloro-4-fluoro-N-((2-(piperazin-1-yl)quinolin- 
3-yl)methyl)aniline, 6D: Dark yellow solid, 
IR νmax (KBr) cm
-1: 3356.18, 2924.22, 2725.54, 
1627.19, 1545.16, 1447.68, 1269.20, 1031.83, 945.27, 
788.59. 1H-NMR (400MHz, DMSO-d6): δH (ppm) 
8.79 (s, 1H), 8.22-8.20 (d, 1H, J = 8 Hz), 8.05-8.03 
(d, 1H, J = 8 Hz), 7.99-7.95 (t, 1H, J = 15.6 Hz), 7.74-
7.70 (t, 1H, J = 15.2 Hz), 7.09-7.02 (m, 2H), 6.67-
6.62 (m, 1H), 6.50-6.48 (d, 1H, J = 9.2 Hz), 4.53 (s, 
2H), 4.17-4.12 (t, 4H, J = 9.6 Hz), 3.61-3.62 (t, 4H, J 
= 9.6 Hz). 13C-NMR (100 MHz, DMSO): δC (ppm) 
42.10, 45.28, 51.40, 114.25, 115.15, 117.60, 121.32, 
121.56, 122.16, 123.44, 127.34, 127.70, 129.15, 
135.59, 144.55, 147.12, 148.45, 157.62. MS (ESI) m/z 
for (370.14): 371.4 (M+H)+, 372.6 (M+2H)+ 
Elemental Analysis: Calculated for C20H20ClFN4 




(370.14): C 64.77%, H 5.44%, N 15.11%; Found: C 
64.75%, H 5.43%, N 15.09%. 
 
3-Chloro-N-((2-(piperazin-1-yl)quinolin-3-yl)methyl) 
aniline, 6E: Dark yellow solid, IR νmax (KBr) cm
-1: 
3326.68, 2967.52, 2747.44, 1626.25, 1535.26, 
1445.52, 1261.45, 1036.23, 947.17, 778.49. 1H-NMR 
(400MHz, DMSO-d6): δH (ppm) 8.79 (s, 1H), 8.22-
8.20 (d, 1H, J = 8.2 Hz), 8.05-8.03 (d, 1H, J = 8 Hz), 
7.99-7.95 (t, 1H, J = 15.6 Hz), 7.74-7.70 (t, 1H, J = 
15.2 Hz), 7.09-7.02 (m, 2H), 6.67-6.62 (m, 2H), 6.50-
6.48 (d, 1H, J = 9.2 Hz), 4.59 (s, 2H), 4.17-4.12  
(t, 4H, J = 9.5 Hz), 3.61-3.62 (t, 4H, J = 9.5 Hz). 13C-
NMR (100 MHz, DMSO): δC (ppm) 42.34, 45.18, 
51.30, 111.62, 113.96, 117.61, 120.74, 121.34, 
122.62, 123.45, 127.31, 127.70, 129.55, 135.15, 
135.90, 148.45, 149.10, 157.16. MS (ESI) m/z for 
(352.15): 353.2 (M+H)+, 354.2 (M+2H)+. Elemental 
Analysis: Calculated for C20H21ClN4 (352.15): C 
68.08%, H 6.00%, N 15.88; Found: C 68.07%, H 
5.98%, N 15.86%. 
 
2,4-Dimethoxy-N-((2-(piperazin-1-yl)quinolin-3-
yl)methyl)aniline, 6F: Dark brown solid, IR νmax (KBr) 
cm-1: 3345.48, 2927.52, 2767.14, 1628.35, 1545.17, 
1449.32, 1258.15, 1041.23, 942.18, 772.43. 1H-NMR 
(400MHz, DMSO-d6): δH (ppm) 11.06 (s, 1H), 9.38 (s, 
1H), 8.51 (s, 1H), 7.90-7.91 (d, 1H, J = 8 Hz), 7.86-7.84 
(d, 1H, J = 8 Hz), 7.67-7.62 (t, 1H, J = 15.2 Hz), 7.49-
7.85 (t, 2H, J = 19.6 Hz), 7.74-7.70 (t, 1H, J = 14.8 Hz), 
7.52-7.49 (t, 1H, J = 14.8 Hz), 6.86-6.76 (m, 3H), 6.64 
(s, 1H), 4.54 (s, 2H), 3.62 (s, 6H), 3.52 (s, 4H), 3.30 (s, 
4H). 13C-NMR (100 MHz, DMSO): δC (ppm) 42.32, 
45.84, 51.05, 55.87, 101.29, 107.40, 115.51, 121.33, 
122.65, 123.74, 127.93, 127.70, 129.50, 130.86, 135.69, 
145.46, 148.42, 162.40, 156.96. MS (ESI) m/z for 
(378.21): 379.4 (M+H)+ Elemental Analysis: Calculated 
for C22H26N4O2 (378.21): C 69.82%, H 6.92%, N 
14.80%; Found: C 69.80%, H 6.91%, N 14.78%. 
 
4-Chloro-N-((2-(piperazin-1-yl)quinolin-3-yl)methyl) 
aniline, 6G: Brown solid, IR νmax (KBr) cm
-1: 
3346.28, 2934.12, 2727.16, 1629.15, 1539.66, 
1447.50, 1262.41, 1033.43, 946.97, 776.29. 1H-NMR 
(400MHz, DMSO-d6): δH (ppm) ) 8.79 (s, 1H), 8.22-
8.20 (d, 1H, J = 8.2 Hz), 8.05-8.03 (d, 1H, J = 8 Hz), 
7.99-7.95 (t, 1H, J = 15.6 Hz), 7.74-7.70 (t, 1H,  
J = 15.2 Hz), 7.09-7.02 (m, 2H), 6.67-6.62 (m, 2H), 
6.50-6.48 (d, 1H, J = 9.2 Hz), 4.59 (s, 2H), 4.17-4.12 
(t, 4H, J = 9.5 Hz), 3.61-3.62 (t, 4H, J = 9.5 Hz). 13C-
NMR (100 MHz, DMSO): δC (ppm) 42.20, 45.28, 
51.30, 114.19, 121.23, 122.16, 123.34, 126.41, 
127.63, 127.75, 129.55, 135.29, 147.40, 148.45, 
155.56. MS (ESI) m/z for (352.15): 353.2 (M+H)+, 
354.3 (M+2H)+. Elemental Analysis: Calculated for 
C20H21ClN4 (352.87): C 68.08%, H 6.00 %, Cl 
10.05%, N 15.88%; Found: C 68.05%, H 5.98 %, Cl 
10.03%, N 15.85%. 
 
3-Methoxy-N-((2-(piperazin-1-yl)quinolin-3-yl)methyl) 
aniline, 6H: Pale yellow solid, IR νmax (KBr) cm
-1: 
3345.28, 2957.12, 2777.09, 1622.21, 1534.45, 
1465.52, 1271.91, 1067.45, 951.97, 777.43. 1H-NMR 
(400MHz, DMSO-d6): δH (ppm) 8.79 (s, 1H), 8.22-
8.20 (d, 1H, J = 8.2 Hz), 8.05-8.03 (d, 1H, J = 8 Hz), 
7.99-7.95 (t, 1H, J = 15.6 Hz), 7.74-7.70 (t, 1H, J = 
15.2 Hz), 7.09-7.02 (m, 2H), 6.67-6.62 (m, 2H), 6.50-
6.48 (d, 1H, J = 9.2 Hz), 4.51 (s, 2H), 4.17-4.12  
(t, 4H, J = 9.5 Hz), 3.83 (s, 3H), 3.61-3.62 (t, 4H, J = 
9.5 Hz). 13C-NMR (100 MHz, DMSO): δC (ppm) 
42.10, 45.48, 51.20, 55.18, 105.26, 105.38, 109.42, 
110.53, 121.36, 122.67, 123.48, 127.39, 127.70, 
129.50, 135.19, 148.24, 148.36, 161.44, 155.66. MS 
(ESI) m/z for (348.20): 349.4 (M+H)+. Elemental 
Analysis: Calculated for C21H24N4O (348.20): C 
72.39%, H 6.94%, N 16.08%; Found: C 72.36%, H 
6.92%, N 16.06%. 
 
3-Methyl-N-((2-(piperazin-1-yl)quinolin-3-
yl)methyl)aniline, 6I: Dark yellow solid, IR νmax  (KBr) 
cm-1: 3345.18, 2956.22, 2767.34, 1689.25, 1536.56, 
1439.72, 1264.35, 1038.14, 948.17, 781.29. 1H-NMR 
(400MHz, DMSO-d6): δH (ppm) 9.34 (s, 1H), 8.34 (s, 
1H), 7.93-7.91 (d, 1H, J = 8 Hz), 7.86-7.84 (d, 1H, J = 8 
Hz), 7.71-7.67 (t, 1H, J = 15.2 Hz), 7.49-7.45 (t, 1H, J = 
15.2 Hz), 7.28-7.26 (d, 1H, J = 8 Hz), 6.90-6.85 (t, 1H, J 
= 18.4 Hz), 6.64 (s, 1H), 6.49 (s, 1H), 4.38 (s, 2H), 4.22-
4.16 (t, 4H, J = 9.6 Hz), 3.83 (s, 3H), 3.61-3.62 (t, 4H, J 
= 9.6 Hz). 13C-NMR (100 MHz, DMSO): δC (ppm) 
20.51, 42.45, 47.28, 123.25, 124.55, 125.45, 127.85, 
128.89, 129.70, 130.20, 130.69, 137.77, 141.54, 157.62. 
MS (ESI) m/z for (332.20): 333.4 (M+H)+. Elemental 
Analysis: Calculated for C21H24N4 (332.20): C 75.87%, 




aniline, 6J: Light yellow solid.IR νmax (KBr) cm
-1: 
3340.82, 28.23.88, 2615.56, 1643.41, 1550.82, 
1435.09, 1265.35,, 1033.88, 941.29, 771.55. 1H-NMR 
(400MHz, DMSO-d6): δH (ppm) 9.34 (s, 1H), 8.34  
(s, 1H), 7.93-7.91 (d, 1H, J = 8 Hz), 7.86-7.84 (d, 1H, 
J = 8 Hz), 7.71-7.67 (t, 1H, J = 15.2 Hz), 7.52-7.48 (t, 
1H, J = 15 Hz), 7.29-7.27 (d, 1H, J = 8.1 Hz), 6.91-6.86 




(t, 1H, J = 18.2 Hz), 6.64 (s, 1H), 6.49 (s, 1H), 4.38 
(s, 2H), 4.23-4.18 (t, 4H, J = 9.5 Hz), 3.83 (s, 3H), 
3.62-3.64 (t, 4H, J = 9.5 Hz). 13C-NMR (100 MHz, 
DMSO): δC (ppm) 20.50, 42.40, 47.26, 123.15, 124.50, 
125.85, 127.75, 128.99, 129.75, 130.0, 130.89, 
137.57, 141.44, 157.60. MS (ESI) m/z for (332.20): 
333.2 (M+H)+. Elemental Analysis: Calculated for 
C21H24N4 (332.20): C 75.87%, H 7.28%, N 16.85%; 
Found: C 75.85%, H 7.25%, N 16.82%. 
 
4-Methoxy-N-((2-(piperazin-1-yl)quinolin-3-
yl)methyl)aniline, 6K: Brown solid, IR νmax (KBr) 
cm-1: 3326.68, 2967.52, 2747.44, 1626.25, 1535.26, 
1445.52, 1261.45, 1036.23, 947.17, 778.49. 1H-NMR 
(400MHz, DMSO-d6): δH (ppm) 9.28 (s, 1H), 8.31  
(s, 1H), 7.93-7.91 (d, 1H, J = 8 Hz), 7.86-7.84 (d, 1H, 
J = 8 Hz), 7.70-7.69 (t, 1H, J = 15 Hz), 7.52-7.48  
(t, 1H, J = 15 Hz), 7.29-7.27 (d, 1H, J = 8.1 Hz), 6.91-
6.86 (t, 1H, J = 18.2 Hz), 6.62 (s, 1H), 6.46 (s, 1H), 
4.31 (s, 2H), 4.22-4.17 (t, 4H, J = 9.4 Hz), 3.83  
(s, 3H), 3.62-3.63 (t, 4H, J = 9.4 Hz). 13C-NMR (100 
MHz, DMSO): δC (ppm) 20.50, 42.40, 47.26, 51.56, 
123.15, 124.50, 125.85, 127.75, 128.99, 129.75, 
130.0, 130.89, 137.57, 141.44, 157.60. MS (ESI) m/z 
for (348.20): 349.3 (M+H)+. Elemental Analysis: 
Calculated for C21H24N4O (348.20): C 72.39%, H 




yl)methyl)aniline, 6L: Brown solid, IR νmax (KBr) 
cm-1: 3376.28, 2948.12, 2755.74, 1647.49, 1544.13, 
1449.61, 1268.24, 1039.81, 945.26, 781.57. 1H-NMR 
(400MHz, DMSO-d6): δH (ppm) 10.80 (s, 1H), 9.35 
(s, 1H), 8.51 (s, 1H), 7.92-7.93 (d, 1H, J = 8.1 Hz), 
7.86-7.84 (d, 1H, J = 8 Hz), 7.66-7.63 (t, 1H, J = 15.3 
Hz), 7.49-7.85 (t, 2H, J = 19.6 Hz), 7.74-7.70 (t, 1H, J 
= 14.8 Hz), 7.52-7.49 (t, 1H, J = 14.8 Hz), 4.55 (s, 
2H), 3.59 (s, 6H), 3.52 (s, 3H), 3.30 (s, 3H). 13C-NMR 
(100 MHz, DMSO): δC (ppm) 42.10, 45.48, 51.20, 
55.18, 105.26, 105.38, 109.42, 110.53, 121.36, 
122.67, 123.48, 127.39, 127.70, 129.50, 135.19, 
148.24, 148.36, 161.44, 155.66. MS (ESI) m/z for 
(378.21): 379.4 (M+H)+. Elemental Analysis: Calculated 
for C22H26N4O2 (378.21): C 69.82%, H 6.92%, N 




Antibacterial and antifungal activity 
The minimal inhibitory concentration (MIC) of all 
synthesized compounds was determined by broth 
microdilution method59. Mueller-Hinton broth and 
Sabouraud’s broth were used as nutrient medium to 
grow bacteria and fungus, respectively. Inoculum size 
for the test strain was adjusted to 106 colony-forming 
unit (CFU) per milliliter by comparing the turbidity. 
Serial dilutions were prepared in primary and 
secondary screening. The control tube containing  
no antibiotic was immediately subcultured (before 
inoculation) by spreading a loopful evenly over a 
quarter of plate of medium suitable for the growth of 
test organism and incubated at 37 oC for bacteria and 
22 oC for fungi overnight. The MIC of the control 
organism was read to check the accuracy of the drug 
concentrations. The lowest concentration inhibiting 
growth of the organism was recorded as the MIC. 
Each test compound was diluted, obtaining  
2,000 µg/mL concentration, as a stock solution. In 
primary screening 1000, 500, 250 and 125 µg/mL 
concentrations of the test compounds were taken. The 
active synthesized compounds found in this primary 
screening were further tested in a second set of 
dilution against all organisms. The drugs found active 
in primary screening were similarly diluted to obtain 
100, 50, 62.5, 25, 12.5 and 6.25 µg/mL concentrations. 
The highest dilution showing at least 99% inhibition 
is taken as MIC. 
All newly synthesized compounds 6(A-L) were 
examined for antimicrobial activity against two gram-
positive bacterial strains (Staphylococcus aureus 
MTCC 96, Streptococcus pyogenes MTCC 442), two 
gram-negative bacterial strains (Escherichia coli 
MTCC 443, Pseudomonas aeruginosa MTCC 1688) 
as well as three fungal strains (Aspergillus clavatus 
MTCC 1323, Candida albicans MTCC 227 and 
Aspergillus niger MTCC 282) using the agar dilution 
method. Ampicillin, Ciprofloxacin and Chloramphenicol 
were used as standard control drugs for antibacterial 
activity, whereas Nystatin and Greseofulvin were 
used as standard control drugs for antifungal activity. 
 
Anti-malarial activity 
A stock solution of 5 mg/mL of each of the test 
samples as well as standards was prepared in DMSO 
and subsequent dilutions were prepared with the 
culture medium. The diluted samples in 20 µL volume 
were added to the test wells so as to obtain final 
concentrations (at fivefold dilutions) ranging between 
0.4 and 100 µg/mL in duplicate well containing 
parasitized cell preparation. The in vitro antimalarial 
assay was carried out in 96 well plates according to  
the microassay protocol of Reickmann and  




co-workers with minor modifications60. The cultures of  
P. falciparum strain were maintained in medium  
RPMI 1640 supplemented with 25 mM HEPES, 1%  
D-glucose, 0.23% sodium bicarbonate and 10% heat 
inactivated human serum. The asynchronous parasites 
of P. falciparum were synchronized after 5%  
D-sorbitol treatment to obtain only the ring stage 
parasitized cells. For carrying out the assay, an initial 
ring stage parasitaemia of 0.8-1.5% at 3% haematocrit 
in a total volume of 200 µl of medium RPMI-1640 was 
determined by Jaswant Singh Bhattacharya (JSB) 
staining to assess the percent parasitaemia (rings) and 
uniformly maintained with 50% RBCs (O+ve). The 
culture plates were incubated at 37oC in a candle jar. 
After 36-40 h incubation, thin blood smears from  
each well were prepared and stained with JSB  
stain. The slides were microscopically observed to 
record maturation of the ring stage parasites into 
trophozoites and schizonts in the presence of different 
concentrations of the test agents. The test concentration 
which inhibited the complete maturation into schizonts 
was recorded as the minimum inhibitory concentration 




MIC of the test compounds against M. tuberculosis 
H37Rv was determined by L. J. agar (MIC) method
61, 
62 where primary 1,000, 500 and 250 µg/mL and 
secondary 200, 100, 50, 25, 12.5, 6.250 and 3.125 
µg/mL dilutions of each test compound were added to 
liquid L.J medium and then media were sterilized by 
inspissation method. A culture of M. tuberculosis 
H37Rv growing on L.J. medium was harvested in 
0.85% saline in bijou bottles. For all test compounds, 
first a stock solution of 2,000 µg/mL concentration 
was prepared in DMSO. These tubes were then 
incubated at 37oC for 24 h followed by streaking of 
M. tuberculosis H37Rv (5×10
4 bacilli per mL). These 
tubes were then incubated at 37±1oC. Growth of 
bacilli was seen after 12, 22 and finally 28 days of 
incubation. Tubes having the compounds were 
compared with control tubes where medium alone  
was incubated with M. tuberculosis H37Rv. The 
concentration at which no development of colonies 
occurred or less than 20 colonies was taken as MIC of 
test compound. The standard strain M. tuberculosis 
H37Rv was tested with known drug rifampicin. 
 
Results and Discussion 
 
Generality and optimization of the reaction 
Initially, we have synthesised 2-chloroquinoline-3-
carbaldehyde (2) from the reaction of acetanilide (1) 
with POCl3 in DMF (N.N-dimethyl formamide) at  
60°C for 5 h. After that, we have successfully 
prepared tert-butyl 4-(3-formylquinolin-2-yl)piperazine- 
1-carboxylate (3) from the reaction of 2-chloroquinoline- 
3-carbaldehyde (2) with tert-butyl piperazine-1-
carboxylate (A) in the presence of K2CO3 in DMF at 
room temperature. After successful synthesis of 
compound (3), we have planned to develop an efficient 
synthesis of derivatives 5(A-L) via reductive amination 
reaction. To identify the optimization reaction conditions, 
initially tert-butyl 4-(3-formylquinolin-2-yl)piperazine- 
1-carboxylate (3) and 3-chloroaniline (4E) was used as 
the model substrates for investigating the effects of 
temperature, various catalyst and solvents (Table I). 
Table I — Optimization of the reaction conditions for the synthesis of tert-butyl 4-(3-(((3-chlorophenyl)amino)methyl)quinolin-2-
yl)piperazine-1-carboxylate (5E) 
Entry Catalyst Solvent Temp (oC) Time Yielda (%) 
1 NaCNBH3 and Acetic acid Methanol RT 1h 82 
2 NaCNBH3 and Acetic acid THF RT 1h 69 
3 NaCNBH3 and Acetic acid Ethanol RT 1h 77 
4 NaBH4 2,2,2-trifluoroethanol RT 1h 52 
5 NaBH4 and Acetic acid Methanol RT 2h 67 
6 NaBH4 and Acetic acid THF RT 2h 60 
7 NaBH4 and Acetic acid Ethanol RT 2h 65 
8 NaBH(OAC)3 and Acetic acid THF RT 2h 58 
9 NaBH(OAC)3 and Acetic acid Dichloroethane RT 2h 62 
10 NaCNBH3 and Acetic acid Methanol 40 1h 80 
11 NaCNBH3 and Acetic acid Methanol 50 1h 76 
12 NaCNBH3 and Acetic acid Methanol 60 1h 70 
a = Isolated yield. 
RT = Room Temperature. 




In a model reaction, initially we used common 
reductive amination condition i.e. NaCNBH3, acetic 
acid in methanol at room temperature, and we found 
that tert-butyl 4-(3-(((3-chlorophenyl) amino)methyl) 
quinolin-2-yl)piperazine-1-carboxylate (5E) could be 
produced in 82% yield within 1h (Table I, Entry 1). 
To improve the yield and to optimize the reaction 
conditions, the same reaction was carried out in the 
presence of solvents like THF and ethanol. However, 
good to moderate yield was observed in THF and 
ethanol (Table I, Entry 2, 3). Thus, we concluded that 
the methanol was the best solvent for this reaction. 
After that, we scrutinized different reducing agents 
in the same reaction conditions. Only moderate yield 
of compound (5E) was observed, when NaBH4 was 
used as a catalyst in 2,2,2-trifluoroethanol (Table I, 
Entry 4). In addition NaBH4 and acetic acid system 
was also screened in different solvents like methanol, 
THF, and ethanol. However, any significant change 
was not observed in product yield, only moderate 
yields were observed in all cases (Table I, Entry 5-7). 
Moreover, NaBH(OAC)3 and acetic acid system was 
also tested by using THF and dichloroethane (DCE) 
as a solvent for this reaction. However, they were not 
found to be efficient as like NaCNBH3 and acetic acid 
(Table I, entry 8, 9). Thus, NaCNBH3 and acetic acid 
in methanol is optimize reaction condition. Further, 
increasing the temperature of the reaction from room 
temperature (RT) to 60 oC, which led to decreasing 
the product yield (Table I, entry 10-12). Thus, 
NaCNBH3 and acetic acid in methanol at room 
temperature is optimized condition for this reaction. 
The optimal conditions found for the compound (5E) 
was successfully applied to the reactions of tert-butyl 
4-(3-formylquinolin-2-yl)piperazine-1-carboxylate (3) 
with different amine 4(A-L) in the presence of 
NaCNBH3 and acetic acid in methanol at room 
temperatur, which afforded corresponding tert-butyl 
4-(3-((phenylamino)methyl)quinolin-2-yl)piperazine-
1-carboxylate derivatives 5(A-L) in good to excellent 
yields within 1h. We tested different aniline derivatives 
to assess the generalization of this protocol. The 
reaction proceeded smoothly and provided excellent 
yields in all cases. Finally, N-((2-(piperazin-1-yl)quinolin- 
3-yl)methyl)aniline derivatives 6(A-L) were synthesised 
by deportation of N-Boc of tert-butyl 4-(3-((phenylamino) 
methyl) quinolin-2-yl)piperazine-1-carboxylate derivatives 
5(A-L) by usind 4M HCl in 1,4-dioxane (Table II). 
After completion of the reaction basify the reaction 
mixture with aq. sodium bicarbonate and extracted 
with DCM. Evaporate DCM layer under vacuum to 
get pure products 6(A-L). 
All synthesized products were easily purified  
by trituration with n-pentane. The purity of the 
synthesized molecules was confirmed by TLC and 
elemental analysis. The structure of the final products 




Compd Code R Time 
(h) 
Yield (%) m.p. (°C) (Lit.) 
6A 3-CH3-4-F 2 82 190-194 
6B 3,4-(OCH3)2 2 78 195-199  
6C 3,4-(F)2 2 81 185-189  
6D 3-Cl-4-F 2 76 188-192  
6E 3-Cl 2 82 196-200  
6F 2,4-(OCH3)2 2 81 204-208  
6G 4-Cl 2 74 201-205  
6H 3-OCH3 2 80 197-199  
6I 3-CH3 2 78 194-196 
6J 4-CH3 2 75 197-198 
6K 4-OCH3 2 81 194-196  
6L 3,5-(OCH3)2 2 76 203-204 
a = Isolated yields 




were well characterized by using spectral analysis 
(IR, Mass, 1H-NMR and 13C-NMR). 
To check the effect of temperature on the reaction, 
we have carried out model reaction at different 
temperature under optimal reaction condition (Figure 5). 
The result displays that at high temperature product may 
degraded to lead lower yield. Best result was obtained 
at room temperature in terms of product yield and 
reaction time. 
 
Proposed reaction mechanism 
We have also defined possible reaction mechanism of 
formation of amide derivatives 6(A-L) (Figure 6). In the 
first step, carbonyl group of aldehyde was protonized in 
the presence of acetic acid. This protonated intermediate 
react amine to form a hemiaminal species, which 
subsequently loses one molecule of water in to form  
the imine. This imine intermediate was reduced in the 
presence of sodium cyanoborohydride to form reductive 
amination product. 
Spectroscopic characterization of quinoline 
hybride piperazine derivatives, 6(A-L) 
IR spectra showed characteristic -NH starching 
peak nearer 3365 cm-1 is corresponding to secondary 
amine group and -CH starching peak nearer 2900-
3000 cm-1 is corresponding to alkane group. In 
addition, characteristic N-H bending peak nearer 1650 
cm-1 is corresponding to secondary amine group. The 
1H-NMR spectrum exhibited a singlet nearer 9.45 
ppm, which indicated a proton of the –NH group. 
While peaks between 3.50 and 3.20 ppm were 
observed for respective piperazine protons. The 13C-
NMR spectrum exhibited peak nearer 155-157 ppm, 
which indicated C-2 carbon of quinolone nucleus, 
while peak nearer 45 ppm, which indicated carbon 
atom of CH2-NH- group. In addition, peaks nearer 
110-140 ppm indicated aromatic carbon atom. The 
ESI-MS spectra of compounds 6(A-L), show 
corresponding (M+1)+ peak as well as (M+2)+ peak. 
In all spectra (M+2)+ peak observed due to presence 
of chloro group. Other spectral data of all compounds 






In vitro antibacterial activity 
All synthesized molecules were screened for their 
in-vitro antibacterial activity (Table III). From the 
bioassay results it is clear that, most of quinoline 
hybride piperazine derivatives 6(A-L) demonstrated 
 
 
Figure 6 — Proposed reaction mechanism 
 
 
Figure 5 — Effect of temperature on conversion of 5E 




significant activity against the mentioned microorganisms 
as compared to standard drugs. In general most of the 
tested compounds showed more potent activity 
against the Gram-positive bacteria (S. aureus) as 
compared to standard drug Ampicillin (MIC 100 
µg/mL), but 50% less active than Chloramphenicol 
(MIC 50 µg/mL) and Ciprofloxacin (MIC 50 µg/mL). 
Only, compound 6F bearing two methoxy group in 
phenyl ring, was found to be the moderate active 
compound that inhibits the gram positive S. aureus 
bacterial growth at the lowest minimum inhibitory 
concentration (MIC) value of 250 µg/mL, which is 
equipotent to Ampicillin (MIC 250 µg/mL). In 
addition, compound 6F, 6H, and 6L displayed equipotent 
activity with 100 µg/mL MIC against S. pyogenus 
bacteria as compared to standard drug Ampicillin, but 
50% less active than Chloramphenicol (MIC 50 µg/mL) 
and Ciprofloxacin (MIC 50 µg/mL). Rest of compounds 
exhibited moderate activity against the S. pyogenus. 
On the other hand, antibacterial activity of all 
synthesized compound against the two Gram-negative 
strains exhibited good activity. In addition, molecules 
6F and 6I (MIC 62.5 µg/mL) displayed excellent 
activity against E. coli as compared to standard drug 
to Ampicillin (MIC 100 µg/mL). Furthermore, 
compounds 6C, 6E, and 6G exhibited good activity 
against E. coli bacterial strain at the minimum 
inhibitory concentration (MIC) value of 100 µg/mL 
equivalent to Ampicillin. Moreover, analogues 6E, 
6H, 6I and 6K (MIC 100 µg/mL) were equipotent to 
Ampicillin (MIC 100 µg/mL) against P. aeruginosa, 
but 50% less active than Chloramphenicol (MIC 50 
µg/mL). Rest of compounds exhibited moderate 
activity against the P. aeruginosa. 
 
In vitro antifungal activity 
Concerning the antifungal activity of tested 
derivatives, only one strain that is C. albicans showed 
excellent sensitivity against some of the tested 
compounds (Table III). Antifungal activity assay 
displayed that among the 6(A-L) derivatives, 
compounds 6A, 6E, 6G and 6J displayed moderate 
activity with MIC 500 μg/mL against C. albicans 
equipotent to Greseofulvin (MIC 500 µg/mL). 
Furthermore, only compound 6K showed excellent 
activity with MIC 250 μg/mL against C. albicans as 
compared to standard drug Greseofulvin (MIC 500 
µg/mL). Moreover, most of compounds showed 
moderate inhibitory efficiency against the A. niger 
and A. clavatus. 
Table III — Antibacterial and antifungal activity (MICs, µg/ml) 
Compd 
 Antibacterial activity  Antifungal activity 
Gram positive 
bacteria 
Gram negative  
bacteria 
  
S.A. S.P. E.C. P.A. C.A. A.N. A.C. 
MTCC 96 MTCC 442 MTCC 443 MTCC 1688 MTCC 227 MTCC 282 
MTCC 
1323 
6A 100 125 125 200 500 >1000 >1000 
6B 100 200 250 200 1000 1000 1000 
6C 200 200 100 250 1000 1000 1000 
6D 100 100 125 250 >1000 1000 1000 
6E 125 125 100 100 500 500 500 
6F 250 100 62.5 125 1000 1000 1000 
6G 100 125 100 200 500 >1000 >1000 
6H 200 100 250 100 1000 500 500 
6I 125 250 62.5 100 500 1000 1000 
6J 100 200 250 200 500 500 500 
6K 100 250 125 100 250 500 500 
6L 100 100 250 200 1000 500 500 
Ampicillin 250 100 100 100 - - - 
Norfloxacin 10 10 10 10 - - - 
Chloramphenicol 50 50 50 50 - - - 
Ciprofloxacin 50 50 25 25 - - - 
Nystatin - - - - 100 100 100 
Greseofulvin - - - - 500 100 100 
 




In vitro anti-malarial activity 
All synthesized compounds 6(A-L) were also 
screened for In vitro antimalarial activity against 
Plasmodium falciparum 3D7-chloroquine-sensitive 
strain. All experiments were performed in duplicate 
and a mean IC50 value is mentioned in Table IV. 
Most of compounds exhibited moderate antimalarial 
activity. 
 
In vitro anti-tuberculosis activity 
All synthesised derivatives 6(A-L) were tested for 
their in vitro antituberculosis activity against 
Mycobacterium tuberculosis H37Rv strain. Isoniazid 
and rifampicin were used as the standard drugs. The 
experimental MIC values of these molecules are 
described in Table V. Among the screened molecules, 
6G showed the good activity (50 mg/mL). Rest  
of compounds exhibited moderate antitubercular 
efficiency. 
 
Structure-activity relationship (SAR) 
The substitution pattern of the arylamine ring at the 
different position was observed to affect biological 
activity (Figure 7). The electronic nature of the 
substituents led to significant effect on bioactivity. 
Compounds possessing -Me and -OMe group on 
phenyl ring led to an increase in the anti-bacterial as 
well as antifungal activity. In addition, the chloro and 
fluoro substituents on phenyl ring was found to be 
active against Gram negative bacterial strain. 
Table IV — In vitro antimalarial activity of compounds 6(A-L) 

















Figure 7 — Structure-activity relationship (SAR) of quinoline hybride piperazine derivatives 6(A-L) 
Table V — In vitro antituberculosis activity of compounds 6(A-L) 



















Furthermore, most of compounds displayed excellent 
potency against S. aureus and C. albicans. 
 
Conclusions 
In summary, we have synthesized and characterized 
new quinoline hybride piperazine derivatives 6(A-L) 
and screened them against some Gram-positive and 
Gram-negative bacteria as well as some fungi strain. 
From the bioassays it is clear that, the most of 
compounds displayed excellent potency against  
S. aureus and C. albicans. All derivatives also possess 
moderate antimalarial as well as antitubercular activity. 
In the present study, compounds 6E, 6F, 6G, 6H, and 
6I displayed highly potent activity against most of the 
tested bacteria and fungi. 
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